86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details
臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-001564-31-BE (EUCTR) | 16/08/2005 | 15/12/2005 | A phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects with Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities - NA | A phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects with Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities - NA | Pulmonary Arterial Hypertension MedDRA version: 7.0;Level: low;Classification code 10037400 | Product Name: Ambrisentan Product Code: BSF 208075 or LU 208075 INN or Proposed INN: Ambrisentan INN or Proposed INN: Ambrisentan INN or Proposed INN: Ambrisentan | Myogen Inc. | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Belgium;Germany |